All In Biotech

Drug Trial Radar · NCT07087262

A Phase I Study of SNH-119014 in Healthy Volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic of SNH-119014 in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Mar 28, 2026

Study completion Mar 28, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.

Conditions

  • Hemoglobinopathy

Interventions

  • SNH-119014Drug

    study drug

  • PlaceboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Abnormal Laboratory Values, Clinically Significant Physical Examination Findings, vital signs, electrocardiogram (ECG) and/or Adverse Events/Serious Adverse Events That Are Related to TreatmentTime frame: up to 7 days or 20 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.